METOJECT SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

METHOTREXATE (METHOTREXATE SODIUM)

Inapatikana kutoka:

MEDEXUS PHARMACEUTICALS INC.

ATC kanuni:

L01BA01

INN (Jina la Kimataifa):

METHOTREXATE

Kipimo:

7.5MG

Dawa fomu:

SOLUTION

Tungo:

METHOTREXATE (METHOTREXATE SODIUM) 7.5MG

Njia ya uendeshaji:

INTRA-ARTERIAL

Vitengo katika mfuko:

0.75ML

Dawa ya aina:

Prescription

Eneo la matibabu:

ANTINEOPLASTIC AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0107545004; AHFS:

Idhini hali ya:

CANCELLED POST MARKET

Idhini ya tarehe:

2022-06-29

Tabia za bidhaa

_ _
_Page 1 of _38_ _
PRODUCT MONOGRAPH
Pr
METOJECT
®
methotrexate sodium solution for injection
methotrexate 10 mg/mL
Single-Use Pre-Filled Syringes
Sterile
THERAPEUTIC CLASSIFICATION
Antirheumatic
Medexus Inc.
35 Nixon Road, Unit 1
Bolton, Ontario
L7E 1K1
Submission Control No.: 237592
Date of Revision:
May 22, 2020
_ _
_Page 2 of _38_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION ........... Error! Bookmark
not defined.
SUMMARY PRODUCT INFORMATION ...................... ERROR! BOOKMARK NOT
DEFINED.
INDICATIONS AND CLINICAL USE ............................ ERROR!
BOOKMARK NOT DEFINED.
CONTRAINDICATIONS .................................................
ERROR! BOOKMARK NOT DEFINED.
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS ..................................................
ERROR! BOOKMARK NOT DEFINED.
DRUG INTERACTIONS
..................................................................................................16
DOSAGE AND ADMINISTRATION
..............................................................................20
OVERDOSAGE
................................................................................................................30
ACTION AND CLINICAL PHARMACOLOGY
............................................................30
STORAGE AND STABILITY
..........................................................................................33
SPECIAL HANDLING INSTRUCTIONS
.......................................................................33
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................34
PART II: SCIENTIFIC INFORMATION
...............................................................................35
PHARMACEUTICAL INFORMATION
..........................................................................35
DETAILED PHARMACOLOGY
.....................................................................................36
TOXICOLOGY
.........................................